ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

Summary

This phase I/II trial studies the side effects and best dose of ABBV-383 and to see how well it works in treating patients with Waldenström macroglobulinemia that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). ABBV-383 is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).

Timeline

Start

2026-10-25

Primary completion

2036-10-25

Completion

2038-10-25

Drugs

Indications